Does RUCAPARIB CAMSYLATE Cause Neoplasm malignant? 19 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Neoplasm malignant have been filed in association with RUCAPARIB CAMSYLATE (Rubraca). This represents 0.2% of all adverse event reports for RUCAPARIB CAMSYLATE.
19
Reports of Neoplasm malignant with RUCAPARIB CAMSYLATE
0.2%
of all RUCAPARIB CAMSYLATE reports
4
Deaths
4
Hospitalizations
How Dangerous Is Neoplasm malignant From RUCAPARIB CAMSYLATE?
Of the 19 reports, 4 (21.1%) resulted in death, 4 (21.1%) required hospitalization.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUCAPARIB CAMSYLATE. However, 19 reports have been filed with the FAERS database.
What Other Side Effects Does RUCAPARIB CAMSYLATE Cause?
Fatigue (2,494)
Nausea (2,219)
Malignant neoplasm progression (1,162)
Decreased appetite (787)
Constipation (763)
Diarrhoea (759)
Vomiting (759)
Asthenia (660)
Adverse event (571)
Carbohydrate antigen 125 increased (562)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which RUCAPARIB CAMSYLATE Alternatives Have Lower Neoplasm malignant Risk?
RUCAPARIB CAMSYLATE vs RUFINAMIDE
RUCAPARIB CAMSYLATE vs RUPATADINE
RUCAPARIB CAMSYLATE vs RUXOLITINIB
RUCAPARIB CAMSYLATE vs SABRIL
RUCAPARIB CAMSYLATE vs SACCHAROMYCES CEREVISIAE